KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) EPS (Basic): 2014-2024

Historic EPS (Basic) for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to $0.12.

  • Palvella Therapeutics' EPS (Basic) fell 99.42% to $0.12 in Q4 2024 from the same period last year, while for Dec 2024 it was -$7.83, marking a year-over-year decrease of 702.31%. This contributed to the annual value of -$7.83 for FY2024, which is 457.53% down from last year.
  • According to the latest figures from Q4 2024, Palvella Therapeutics' EPS (Basic) is $0.12, which was up 103.05% from -$3.94 recorded in Q3 2024.
  • Palvella Therapeutics' 5-year EPS (Basic) high stood at $20.52 for Q4 2023, and its period low was -$14.15 during Q1 2023.
  • In the last 3 years, Palvella Therapeutics' EPS (Basic) had a median value of -$0.14 in 2022 and averaged -$0.58.
  • Over the last 5 years, Palvella Therapeutics' EPS (Basic) had its largest YoY gain of 18,754.55% in 2023, and its largest YoY loss of 20,114.29% in 2023.
  • Palvella Therapeutics' EPS (Basic) (Quarterly) stood at -$0.26 in 2020, then skyrocketed by 50.00% to -$0.13 in 2021, then grew by 15.38% to -$0.11 in 2022, then soared by 18,754.55% to $20.52 in 2023, then slumped by 99.42% to $0.12 in 2024.
  • Its EPS (Basic) was $0.12 in Q4 2024, compared to -$3.94 in Q3 2024 and -$2.47 in Q2 2024.